MP80-06 EVALUATION OF ‘PROGRAMMED DEATH-1’ / ‘PROGRAMMED DEATH LIGAND 1 AND 2’ PATHWAY IN TUMOR SAMPLES OF SEMINOMA AND NON-SEMINOMA, AND ITS PROGNOSTIC ROLE IN TESTICULAR CANCERS

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Penis/Testis/Urethra: Benign Disease & Malignant Disease III1 Apr 2017MP80-06 EVALUATION OF ‘PROGRAMMED DEATH-1’ / ‘PROGRAMMED DEATH LIGAND 1 AND 2’ PATHWAY IN TUMOR SAMPLES OF SEMINOMA AND NON-SEMINOMA, AND ITS PROGNOSTIC ROLE IN TESTICULAR CANCERS Asgar Garayev, Emine Bozkurtlar, Deniz Filinte, Haydar Kamil Cam, Ferruh Simsek, and Ilker Tinay Asgar GarayevAsgar Garayev More articles by this author , Emine BozkurtlarEmine Bozkurtlar More articles by this author , Deniz FilinteDeniz Filinte More articles by this author , Haydar Kamil CamHaydar Kamil Cam More articles by this author , Ferruh SimsekFerruh Simsek More articles by this author , and Ilker TinayIlker Tinay More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2511AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Inhibition of the Programmed Death Receptor 1 (PD-1) and Programmed Death Receptor Ligand 1 (PD-L1) pathway is a promising treatment alterative and improves survival in a number of different cancers, including melanoma and kidney cancer. Recent data showed that evaluation of PD-1 and PD-L1 expression in various tumors could be used for the prognostic value of anti-PD-1 or anti-PD-L1 treatments. We aimed to analyze the expressions of PD-1, PD-L1 and PD-L2 in the testicular germ cell tumors (TGCTs) and evaluate their potential as immunotherapeutic target. METHODS Formalin-fixed paraffin-embedded tumor specimens of 60 patients diagnosed with TGCTs were evaluated, where there are 24 pure seminomas and 36 mixed germ cell tumors. Immunohistochemistry was performed to evaluate expression of PD-1 (EH33 antibody), PD-L1 (E1L3N antibody), PD-L2 (D7U8C antibody), CD8 (4B11 antibody) and CD4 (368) using monoclonal antibodies mentioned in the brackets. RESULTS None of seminoma specimens exhibited PD-L1 expression, where PD-L1 expression was found in 19.4% of mixed germ cell tumors. None of seminomas and nonseminomas expressed PD-L2. In mixed germ cell tumors PD-1 negativity or poor expression of PD-1 in both stromal and intra-tumoral lymphocytes was associated with statistically lower overall survival (figure) and high progression and mortality rates. CONCLUSIONS The PD-1 expression profiles in mixed germ cell tumors could help to identify patients with poor prognosis potential and those patients could benefit from early therapeutic interventions and immunotherapeutic strategies using anti-PD1 and anti-PDL1 antibodies. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1082-e1083 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Asgar Garayev More articles by this author Emine Bozkurtlar More articles by this author Deniz Filinte More articles by this author Haydar Kamil Cam More articles by this author Ferruh Simsek More articles by this author Ilker Tinay More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...